# EDGAR Filing Document

**Accession Number:** 0001708599
**File Stem:** 0001104659-23-023039
**Filing Date:** 2023-2
**Character Count:** 11746
**Document Hash:** 4d585f037b9ea532b9367ca991841592
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-023039.hdr.sgml**: 20230217

**ACCESSION NUMBER**: 0001104659-23-023039

**CONFORMED SUBMISSION TYPE**: SC 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230217

**DATE AS OF CHANGE**: 20230217

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AgeX Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001708599
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 821436829
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90737
- **FILM NUMBER:** 23640257

**BUSINESS ADDRESS:**
- **STREET 1:** 1101 MARINA VILLAGE PARKWAY
- **STREET 2:** SUITE 201
- **CITY:** ALAMEDA
- **STATE:** CA
- **ZIP:** 94501
- **BUSINESS PHONE:** 510-671-8370

**MAIL ADDRESS:**
- **STREET 1:** 1101 MARINA VILLAGE PARKWAY
- **STREET 2:** SUITE 201
- **CITY:** ALAMEDA
- **STATE:** CA
- **ZIP:** 94501
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Juvenescence Ltd
- **CENTRAL INDEX KEY:** 0001724307
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** Y8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 1ST FLOOR, VIKING HOUSE
- **CITY:** ST PAULS SQUARE, RAMSEY
- **STATE:** Y8
- **ZIP:** IM8 1GB
- **BUSINESS PHONE:** 441624639396

**MAIL ADDRESS:**
- **STREET 1:** 1ST FLOOR, VIKING HOUSE
- **CITY:** ST PAULS SQUARE, RAMSEY
- **STATE:** Y8
- **ZIP:** IM8 1GB

SECURITIES AND EXCHANGE COMMISSION<br> WASHINGTON, DC 20549

**SCHEDULE 13D**<br> **(Rule 13d-101)**

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT<br> TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT<br> TO RULE 13d-2(a)

(Amendment No. 22)

**AGEX THERAPEUTICS, INC.**

(Name of Issuer)

**Common Stock, par value $0.0001 per share**

(Title of Class of Securities)

**00848H108**

(CUSIP number)

David Gill

c/o Juvenescence Limited

1st Floor, Viking House

St Pauls Square, Ramsey

Isle of Man, IM8 1GB

+441624639393

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

**February 15, 2023**

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ¨.

*Note*: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. *See* Rule 13d-7(b) for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act by shall be subject to all other provisions of the Act (however, *see* the *Notes*).

1. NAME OF REPORTING PERSON **Juvenescence Limited** 

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ◻ (b) ◻

3. SEC USE ONLY

4. SOURCE OF FUNDS **WC** 

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
 ITEMS 2(d) OR 2(e) ◻

6. CITIZENSHIP OR PLACE OF ORGANIZATION **Isle of Man** 

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;NUMBER OF <br> SHARES <br> BENEFICIALLY<br> OWNED BY EACH<br> REPORTING <br> PERSON WITH | &nbsp;&nbsp;7. | &nbsp;&nbsp; SOLE VOTING POWER<br>**66,652,153<sup>1</sup>** |
| &nbsp;&nbsp;NUMBER OF <br> SHARES <br> BENEFICIALLY<br> OWNED BY EACH<br> REPORTING <br> PERSON WITH | &nbsp;&nbsp;8. | &nbsp;&nbsp; SHARED VOTING POWER<br>**0** |
| &nbsp;&nbsp;NUMBER OF <br> SHARES <br> BENEFICIALLY<br> OWNED BY EACH<br> REPORTING <br> PERSON WITH | &nbsp;&nbsp;9. | &nbsp;&nbsp; SOLE DISPOSITIVE POWER<br>**66,652,153<sup>1</sup>** |
| &nbsp;&nbsp;NUMBER OF <br> SHARES <br> BENEFICIALLY<br> OWNED BY EACH<br> REPORTING <br> PERSON WITH | &nbsp;&nbsp;10. | &nbsp;&nbsp; SHARED DISPOSITIVE POWER<br>**0** |

---

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON **66,652,153<sup>1</sup>** 

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ◻

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 **75.6%** 

14. TYPE OF REPORTING PERSON **CO** 

<sup>1</sup> Comprised of (i) 16,447,500 shares of Common Stock held directly, (ii) 3,670,663 shares of Common Stock that may be acquired on exercise of Warrants issued or to be issued in connection with advances under the New Facility, (iii) 9,600,657 shares of Common Stock that may be acquired on exercise of Warrants issued or to be issued in connection with advances under the A&R Secured Note, (iv) 13,333,333 shares of Common Stock that may be issued upon conversion of outstanding amounts under the New Facility at the closing price of the Common Stock on February 15, 2023 and (v) 23,600,000 shares of Common Stock that may be issued upon conversion of outstanding amounts under the A&R Secured Note at the closing price of the Common Stock on February 15, 2023 (capitalized terms are defined below).

**SCHEDULE 13D**

This amendment (the "Amendment") amends and supplements the beneficial ownership statement on Schedule 13D filed with the Securities and Exchange Commission on August 16, 2019 (as amended by Amendment No. 1 filed April 6, 2020, Amendment No. 2 filed July 31, 2020, Amendment No. 3 filed October 7, 2020, Amendment No. 4 filed November 11, 2020, Amendment No. 5 filed January 12, 2021, Amendment No. 6 filed February 9, 2021, Amendment No. 7 filed February 17, 2021, Amendment No. 8 filed May 11, 2021, Amendment No. 9 filed May 11, 2021, Amendment No. 10 filed September 14, 2021, Amendment No. 11 filed November 2, 2021, Amendment No. 12 filed November 18, 2021, Amendment No. 13 filed December 13, 2021, Amendment No. 14 filed February 14, 2022, Amendment No. 15 filed February 22, 2022, Amendment No. 16 filed April 11, 2022, Amendment No. 17 filed June 24, 2022, Amendment No. 18 filed August 23, 2022, Amendment No. 19 filed October 25, 2022, Amendment No. 20 filed December 15, 2022 and Amendment No. 21 filed January 25, 2023, the "Original Statement"). The Original Statement, as amended by this Amendment (the "Statement") is filed on behalf of Juvenescence Limited, an Isle of Man company (the "Reporting Person"), and relates to the shares of Common Stock of AgeX Therapeutics, Inc., par value $0.0001 per share (the "Common Stock").

Capitalized terms used but not defined in this Amendment have the meanings ascribed to them in the Original Statement. This Amendment amends the Original Statement as specifically set forth herein. Except as set forth below, all previous Items in the Original Statement remain unchanged.

**Item 5.** **Interest in Securities of the Issuer.**

Item 5 of the Original Statement is hereby amended and restated in its entirety to read as follows:

(a) The Reporting Person beneficially owns an aggregate of 66,652,153 shares of Common Stock, representing (i) 16,447,500 shares of Common Stock held directly, (ii) 3,670,663 shares of Common Stock that may be acquired on exercise of Warrants issued or to be issued in connection with advances under the New Facility (as defined below), (iii) 9,600,657 shares of Common Stock that may be acquired on exercise of Warrants issued or to be issued in connection with advances under the A&R Secured Note (as defined below), (iv) 13,333,333 shares of Common Stock that may be issued upon conversion of outstanding amounts under the New Facility at the closing price of the Common Stock on February 15, 2023 and (v) 23,600,000 shares of Common Stock that may be issued upon conversion of outstanding amounts under the A&R Secured Note at the closing price of the Common Stock on February 15, 2023. This aggregate amount represents approximately 75.6% of the Issuer's outstanding common stock, based upon 37,947,152 shares outstanding as of November 7, 2022, as reported on the Issuer's Quarterly Report filed on Form 10-Q on November 10, 2022, and giving effect to the exercise of the Warrants and conversion of amounts outstanding under the A&R Secured Note, New Facility and the Loan Agreement (and assuming the Amendment Caps do not apply).

(b) The information in Items 7 through 10 of each cover page is incorporated by reference into this Item 5(b).

(c) Except for the information set forth in Item 6, which is incorporated by reference into this Item 5(c), the Reporting Persons have effected no transactions relating to the Common Stock during the past 60 days.

(d) - (e) Not applicable.

**Item 6.** **Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.**

Item 6 of the Original Statement is hereby supplemented as follows:

On February 9, 2023, the Issuer and the Reporting Person entered into an Amended and Restated Secured Convertible Promissory Note (the "A&R Secured Note") which amends and restates the Secured Note and provides that the Issuer may borrow up to an additional $2,000,000 from the Reporting Person until May 9, 2023 subject to the Reporting Person's discretion to approve each loan draw. The Issuer may not draw more than $1 million in any single draw. The Repayment Date on which the outstanding principal balance of the A&R Secured Note will become due and payable shall be February 14, 2024, consistent with the terms of the Secured Note.

The other material provisions of the Secured Note, including but not limited to those pertaining to loan origination fees, default provisions, provisions governing the rights of the Issuer and the Reporting Person to convert the loan balance and any accrued but unpaid origination fees into shares of the Issuer common stock, and provisions requiring the Issuer to issue common stock purchase warrants to the Reporting Person in connection with borrowings remain in effect and will apply to any draw down of the additional $2,000,000 credit available under the A&R Secured Note.

In connection with the A&R Secured Note, the Issuer and Reporting Person entered into a Reaffirmation and Amendment Agreement (the "Reaffirmation Agreement") pursuant to which the Issuer reaffirmed its obligations under certain agreements between the Issuer and the Reporting Person that originally pertained to the Secured Note, including but not limited to (i) the Security Agreement, (ii) a Registration Rights Agreement, as amended, and (iii) the 2022 Warrant Agreement. The Reaffirmation Agreement also amended the 2022 Warrant Agreement to provide that the 2022 Warrant Agreement also pertains to the A&R Secured Note and any future amendment of the Secured Note.

On February 15, 2023, the Reporting Person funded an additional advance to the Issuer in the principal amount of $1,000,000. On February 15, 2023, subject to notification by NYSE American that the Issuer's supplemental listing application for the additional Warrant shares have been approved, the Issuer issued to the Reporting Person a Warrant to purchase 801,924 shares of Common Stock at an exercise price of $0.6235 per share, representing the last closing price of the Common Stock on the NYSE American market prior to the drawdown notice, issuable under Clause 3.4 of the A&R Secured Note.

**SIGNATURES**

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this Statement is true, complete and correct.

Date: February 17, 2023

---

| | |
|:---|:---|
| **JUVENESCENCE LIMITED** | **JUVENESCENCE LIMITED** |
| By: | /s/ Gregory H. Bailey |
| Name: | Gregory H. Bailey |
| Title: | Executive Chairman |

---